ProCE Banner Activity

What Cardiologists Need to Know About Diagnosing and Treating PAH

Clinical Thought

Pulmonary arterial hypertension is a complex disease that continues to see high mortality rates. Here are my thoughts on best practices cardiologists can heed when screening, diagnosing, and treating patients to improve outcomes.

Released: November 20, 2023

Share

Faculty

Vallerie V. McLaughlin

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported through an independent educational grant from Merck & Co.

Merck & Co.

Disclosure

Primary Author

Vallerie V. McLaughlin, MD

Kim A. Eagle, MD Endowed Professor of Cardiovascular Medicine
Interim Chief Clinical Officer, Ambulatory Care Services
Director, Pulmonary Hypertension Program
Michigan Medicine
Ann Arbor, Michigan

Vallerie McLaughlin, MD: consultant/advisor/speaker: Aerami, Aerovate, Caremark, CorVista, Enzyvant, Gossamer Bio, Janssen, Merck, United Therapeutics, Vertex; researcher: Aerovate, Enzyvant, Gossamer Bio, Janssen, Merck, SoniVie